| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2a interim results example | neflamapimod nonfluent variant primary progressive aphasia (nfvPPA) | Phase 2a | — | Small Molecules | Nervous System | ||
Phase 2a interim results example | neflamapimod nonfluent variant primary progressive aphasia (nfvPPA) | Phase 2a | — | Small Molecules | Nervous System | ||
Phase 2a interim results example | neflamapimod nonfluent variant primary progressive aphasia (nfvPPA) | Phase 2a | — | Small Molecules | Nervous System |
Recent Updates
Recently added Catalysts
CervoMed Inc.$3.88
-0.62 (-13.72%)
D 25Pipeline Score Richly Valued Biotech · Clinical
Market Cap
35.46 M
EPS
-2.97
P/E Ratio
-1.29 $
Value Trade
127.99 K
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
5.14 M
Operating CF
-8.02 M
Total Assets
15.11 M
Total Liabilities
4.50 M
Equity
10.62 M
D/E Ratio
12,345
-10.83 %
Week
-14.18 %
1 Month
-6.84 %
3 Month
-8.05 %
6 Month
-91.34 %
5 Year
-100 %
All Time
Cash Data
Cash Position
12.92 M
Monthly Burn
2.67 M
Runway
3.9 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
3.54 M
52 Week Range
3.51 - 13.13
% held by Insiders
48.2 %
% held by Institutions
19.11 %
Enterprise Value
14.60 M
Total Shares
9.25 M
Short %
4.46 %
Float Shares
5.89 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D25
Pipeline Score $2M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.1x
rNPV / MCap Top 26%
Micro Cap (rank 671 of 905)
Percentile RankCervoMed Inc. faces pipeline headwinds (25/100), with $184M risk-adjusted pipeline value, led by Neflamapimod in Moderate to Severe Acute Ischaemic Stroke (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| neflamapimod Small molecule | Dementia With Lewy Bodies (DLB) | Phase 2 | NCT06815965 | 21% | $184M | ACTIVE NOT_RECRUITING | 25 | SLOW | D (23) | Apr 1, 2026 | MODERATE_RISK | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
neflamapimod | Dementia with Lewy Bodies | Phase 2b | 2025-07-29 | |||
neflamapimod | Dementia with Lewy Bodies | Phase 2b | 2025-07-29 | |||
neflamapimod | Dementia with Lewy Bodies | Phase 2b | 2025-07-29 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CRVO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
CRVO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CRVO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CRVO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CRVO Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
CRVO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CRVOCervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
CervoMed Inc. will participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit on June 15, 2026. The company will engage in a fireside chat and one-on-one investor meetings. CervoMed is focused on developing treatments for age-related brain disorders, including its lead candidate, neflamapimod, which has shown promise in clinical trials.
Read more →CRVOCervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies
CervoMed Inc. announced a $10.5 million private placement to extend its cash runway into 2027 and focus on establishing a partnership to advance neflamapimod into Phase 3 for dementia with Lewy bodies (DLB). The company has achieved significant progress in clinical trials and is aligned with regulatory bodies on a potential registration path for neflamapimod. Upcoming milestones include data from ongoing trials in related neurological disorders.
Read more →CRVOCervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference
CervoMed Inc. announced that its drug candidate neflamapimod will be featured at the AD/PD 2026 conference in Copenhagen. The presentations will focus on the drug's efficacy in dementia with Lewy bodies (DLB) and its planned Phase 3 trial. CervoMed aims to enrich the patient population for the trial by excluding those with Alzheimer’s disease co-pathology. The company is also sponsoring a symposium on advancements in DLB research.
Read more →CRVOCervoMed to Participate in Upcoming Investor Conferences
CervoMed Inc. (NASDAQ: CRVO) announced its participation in two investor conferences in March 2026. The company will hold 1x1 meetings at the Leerink Global Healthcare Conference and a fireside chat at the ROTH Conference. CervoMed is developing neflamapimod for age-related brain disorders and plans to initiate a Phase 3 trial later this year.
Read more →CRVOCervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies
CervoMed has announced the selection of a 50mg TID dosing regimen for its planned Phase 3 trial of neflamapimod in patients with dementia with Lewy bodies. This decision follows a successful Phase 1 study that demonstrated a favorable pharmacokinetic profile for a new stable crystal form of the drug. The company aims to align plasma drug concentrations with those observed in prior successful trials.
Read more →CRVOCervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis
CervoMed's neflamapimod has been selected for the UK EXPERTS-ALS platform, which aims to expedite the evaluation of treatments for amyotrophic lateral sclerosis (ALS). The trial will assess the drug's impact on neurofilament light chain (NfL) levels in ALS patients, with the first participant expected to be dosed by the end of 2026. This endorsement is based on neflamapimod's mechanism of action and previous clinical efficacy in related conditions.
Read more →CRVOCervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)
CervoMed presented promising data from its Phase 2b study of neflamapimod at the CTAD Conference. The treatment significantly reduced plasma GFAP levels and improved the A42/40 ratio in patients with Dementia with Lewy Bodies (DLB). These findings suggest neflamapimod may effectively target neuroinflammation and neurodegeneration, supporting its potential for future Phase 3 trials.
Read more →CRVOCervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
CervoMed Inc. announced that neflamapimod will be featured in two presentations at the upcoming CTAD Conference. The late-breaking oral session will present full results from the Phase 2b RewinD-LB trial, while a poster session will highlight findings on neurodegeneration biomarkers. The drug aims to address the unmet need in treating Dementia with Lewy Bodies.
Read more →CRVOCervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
CervoMed reported its Q3 2025 financial results, highlighting alignment with the FDA on the Phase 3 trial design for neflamapimod in dementia with Lewy bodies (DLB). The Phase 2b RewinD-LB trial demonstrated significant clinical benefits and biomarker improvements. The company anticipates initiating a global pivotal trial in late 2026 and has ongoing studies in related dementia conditions.
Read more →CRVOCervoMed Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy Bodies
CervoMed has received FDA alignment on its Phase 3 trial design for neflamapimod, aimed at treating dementia with Lewy bodies. The trial will include approximately 300 patients and is set to begin in the second half of 2026. This marks a significant milestone for CervoMed, as there are currently no approved therapies for this condition in the U.S. or EU.
Read more →CRVOCervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley
CervoMed Inc. has appointed David Quigley to its Board of Directors, enhancing its strategic capabilities as the company prepares for a Phase 3 trial for neflamapimod in dementia with Lewy bodies (DLB). Quigley's extensive experience in life sciences and private equity is expected to support CervoMed's commercialization efforts. The company anticipates FDA feedback on its trial design in late 2025.
Read more →CRVOCervoMed to Present at the Emerging Growth Conference
CervoMed Inc. (NASDAQ: CRVO) will present at the Emerging Growth Conference on October 22, 2025. Matthew Winton, Ph.D., will lead the corporate presentation, discussing the company's focus on age-related neurologic disorders and their investigational drug, neflamapimod. This drug aims to address synaptic dysfunction linked to neurodegenerative diseases, following a completed Phase 2b trial.
Read more →CRVOCervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies
CervoMed has announced promising results from its Phase 2b trial of neflamapimod for dementia with Lewy bodies, showing significant improvements in clinical outcomes and biomarker reductions. The trial results suggest that neflamapimod may be effective for patients without Alzheimer's disease co-pathology. The company is awaiting FDA feedback on the Phase 3 trial design, expected later this quarter.
Read more →CRVOCervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer
CervoMed Inc. has appointed Matthew Winton, Ph.D., as Chief Commercial and Business Officer. Dr. Winton brings nearly two decades of experience in biotechnology and will play a crucial role as the company progresses into late-stage Phase 3 development of neflamapimod, a treatment for dementia with Lewy bodies. His expertise is expected to enhance CervoMed's strategic growth and commercialization efforts.
Read more →CRVOCervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
CervoMed Inc. will participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025. The company will engage in a panel discussion titled 'Small Firms Tackling Blockbuster Indications' and hold one-on-one meetings. CervoMed is focused on developing neflamapimod, a treatment for age-related neurologic disorders, which has shown potential in recent trials.
Read more →CRVOCervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference
CervoMed Inc. presented the potential benefits of neflamapimod for treating Dementia with Lewy Bodies at the 150th Annual American Neurological Association conference. The Phase 2b trial demonstrated a 74% reduction in the risk of clinically significant worsening. The company is preparing to begin a Phase 3 trial and expects to align with the FDA on its design by late 2025.
Read more →Competitive Position
How CRVO ranks across every disease it competes inCompetitive Position is a premium feature
See how CRVO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial